The trademark application ATB Therapeutics was filed by ATB Therapeutics, a corporation established under the laws of the Kingdom of Belgium (the "Applicant"). The application was published for oppositions on December 13, 2020, and it was registered by office on March 22, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on April 5, 2022.
The Refusal with reference B 018229149 was partially rejected according to Article 7(1)(b) EUTMR with decision issued on August 24, 2020 by the EUIPO.
Goods And Services
The mark was filed in class 1 with Active chemicals for the production of anti-cancer drugs, Monoclonal antibodies for scientific purposes, Proteins for use in recombinant DNA technology [other than for medical use], Antibody reagents for scientific purposes.
The mark was filed in class 5 with Preparations for the treatment of cancer, pharmaceutical preparations for the treatment of cancer, biological preparations for the treatment of cancer, pharmaceutical products for the treatment and prevention of cancer, pharmaceutical preparations for the suppression of tumors and pharmaceutical preparations for use in oncology, chemotherapeutics, antibodies..
The mark was filed in class 42 with Laboratory services relating to the production of monoclonal antibodies, Research and development services in the field of antibodies.